These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9558419)

  • 1. Accessing investigational anticancer agents outside of clinical trials.
    Montello MJ; Greenblatt JJ; Fallavollita A; Shoemaker D
    Am J Health Syst Pharm; 1998 Apr; 55(7):651-2, 660. PubMed ID: 9558419
    [No Abstract]   [Full Text] [Related]  

  • 2. Increasing access to investigational drugs.
    Christian M
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):90-1. PubMed ID: 16163167
    [No Abstract]   [Full Text] [Related]  

  • 3. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 5. Access to 'investigational' cancer drugs: perspective of a trainee.
    Kuo JC
    Intern Med J; 2015 Feb; 45(2):235. PubMed ID: 25650544
    [No Abstract]   [Full Text] [Related]  

  • 6. How does a drug get to phase III trials?
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084
    [No Abstract]   [Full Text] [Related]  

  • 7. Slow start to phase 0 as researchers debate value.
    Twombly R
    J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
    [No Abstract]   [Full Text] [Related]  

  • 8. Expanded Access Allows for Compassionate Use of Investigational Cancer Drugs.
    Miller D
    ONS Connect; 2015 Jun; 30(2):47. PubMed ID: 26137830
    [No Abstract]   [Full Text] [Related]  

  • 9. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 10. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

  • 11. Dilemmas in the compassionate supply of investigational cancer drugs.
    Lewis JR; Lipworth W; Kerridge I; Doran E
    Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New NCI drug formulary cuts red tape.
    Weintraub A
    Lab Anim (NY); 2017 Jun; 46(7):285. PubMed ID: 28644447
    [No Abstract]   [Full Text] [Related]  

  • 13. Executive summary from the final reports of the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS.
    Oncology (Williston Park); 1991 Apr; 5(4):16, 18-9. PubMed ID: 1831034
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese universal health care faces a crisis in cancer treatment.
    Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
    Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer, access to investigational drugs, and patient rights in the U.S.A. and India.
    Sheehan HE
    Indian J Med Ethics; 2008; 5(4):170-2; discussion 173. PubMed ID: 18988376
    [No Abstract]   [Full Text] [Related]  

  • 17. The National Cancer Institute: cancer drug discovery and development program.
    Grever MR; Schepartz SA; Chabner BA
    Semin Oncol; 1992 Dec; 19(6):622-38. PubMed ID: 1462164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 19. "Right to Try" Laws: The Gap between Experts and Advocates.
    Dresser R
    Hastings Cent Rep; 2015; 45(3):9-10. PubMed ID: 25944200
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of investigational radiation modifiers.
    Colevas AD; Brown JM; Hahn S; Mitchell J; Camphausen K; Coleman CN;
    J Natl Cancer Inst; 2003 May; 95(9):646-51. PubMed ID: 12734315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.